3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
venetoclax
152
Cytarabine
114
Cyclophosphamide
110
Specimen Handling
101
Azacitidine
99
fludarabine
89
Biopsy
76
Rituximab
48
Methotrexate
45
Daunorubicin
44
fludarabine phosphate
42
Vincristine
38
Dexamethasone
37
Magnetic Resonance Spectroscopy
36
Injections
34
Decitabine
34
blinatumomab
31
Granulocyte Colony-Stimulating Factor
30
Mycophenolic Acid
29
Whole-Body Irradiation
28
Prednisone
28
Idarubicin
28
ibrutinib
27
Tacrolimus
27
Etoposide
27
Doxorubicin
27
Busulfan
27
Melphalan
24
acalabrutinib
23
Mercaptopurine
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hizentra
×
Other hematologic neoplasm
×
90 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled